. 2022 Jul 19;17:128. doi: 10.1186/s13014-022-02094-3

Table 4.

Studies involving Linac-SBRT and CK-SBRT for early-stage NSCLC

	T factor (n)	LC (%)	OS (%)	Dose	Prescription	Lung toxicity
Linac-SBRT
Timmerman et al. [4]	T1 (44)	3-year: 97.6	3-year: 55.8	54 Gy/3 Fr	PTV D₉₅	Grade 3: 4%
Timmerman et al. [4]	T2 (11)
Nagata et al. [5]	T1 (169)	Operable	Operable	48 Gy/4 Fr	Isocenter	Operable
		3-year: 85.4	3-year: 76.5			Grade 3: 3%
		Inoperable	Inoperable			Inoperable
		3-year: 87.3	3-year: 59.9			Grade 3: 8%
						Grade 4: 1%
Koshy et al. [21]	T1 (334)	NA	3-year: 50	48–60 Gy/3–4 Fr	NA	NA
Koshy et al. [21]	T2 (164)		5-year: 30
Matsuo et al. [25]	T1 (73)	3-year: 86.8	3-year: 58.6	48 Gy/4 Fr	Isocenter	Grade 3: 3%
Matsuo et al. [25]	T2 (28)		5-year: 46.7
CK-SBRT
Bahig et al. [10]	T1 (123)	2-year: 96	2-year: 87	40–60 Gy/3–5 Fr	PTV D₉₅	Grade 3: 1%
Bahig et al. [10]	T2 (27)				75% isodose	Grade 5: 2% (with IPF)
Heal et al. [11]	T1 (63)	2-year: 94	3-year: 37	50–60 Gy/3–5 Fr	NA	Grade 3: 2%
Heal et al. [11]	T2 (37)	3-year: 84
van der Voort van Zyp et al. [12]	T1 (39)	2-year	1-year: 83	45 or 60 Gy/3 Fr	PTV D₉₅	Grade 3: 4%
	T2 (31)	45 Gy: 78	2-year: 62		70–85% isodose
		60 Gy: 96
Present study	T1a/b (61)	2-year: 97	2-year: 90	54–60 Gy/3 Fr	GTV D₉₉	Grade 3: 1%
	T1c (30)				70–80% isodose
	T2 (5)

Linac-SBRT linear accelerator-based stereotactic body radiotherapy, CK-SBRT CyberKnife®-based stereotactic body radiotherapy, NSCLC non-small cell lung carcinoma, PTV planning target volume, NA not available, IPF idiopathic pulmonary fibrosis, GTV gross tumor volume, Fr fractions